MDWD - メディウ―ンド (MediWound Ltd.) メディウ―ンド

 MDWDのチャート


 MDWDの企業情報

symbol MDWD
会社名 Mediwound Ltd. (メディウ―ンド)
分野(sector) Consumer Durables   耐久消費財
産業(industry) Specialty Chemicals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing manufacturing and commercializing therapeutics products in the fields of severe burns chronic and other hard-to-heal wounds connective tissue disorders and other indications. The Company''s product NexoBrid is indicated for the removal of dead or damaged tissue known as eschar in adults with deep partial- and full-thickness thermal burns also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product EscharEx is a topical biological drug which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.   メディウ―ンドはイスラエルのバイオ医薬品会社。重度熱傷、慢性疾患、その他治癒が困難な創傷、膠原病などの分野で有効な治療法がない医療ニ―ズに対応する製品の開発、製造、商業化に従事する。同社のバイオ医薬品「NexoBrid」は痂皮の切除用製品として、欧州医薬品庁から承認済みである。   MediWound is a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Its strategy is centered around its validated enzymatic platform technology, focused on next-generation bio-active therapies for burn and wound care and biological medicinal products for tissue repair.
本社所在地 42 Hayarkon Street Yavne 8122745 ISR
代表者氏名 Stephen T. Wills スティーブン・T・ウィルズ
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +972 8-932-4010
設立年月日 36526
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 76人
url www.MediWound.com
nasdaq_url https://www.nasdaq.com/symbol/mdwd
adr_tso
EBITDA EBITDA(百万ドル) -12.75100
終値(lastsale) 6.36
時価総額(marketcap) 172857416.04
時価総額 時価総額(百万ドル) 165.24730
売上高 売上高(百万ドル) 2.82000
企業価値(EV) 企業価値(EV)(百万ドル) 138.24330
当期純利益 当期純利益(百万ドル) -14.47300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Mediwound Ltd revenues increased 26% to $1.6M. Net loss decreased 1% to $8.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development net decrease of 65% to $1.2M (expense) General and administrative decrease of 40% to $989K (expense).

 MDWDのテクニカル分析


 MDWDのニュース

   Is Mediwound Ltd (MDWD) A Good Stock To Buy?  2021/06/18 14:48:23 Insider Monkey
   MediWound completes enrollment for interim assessment of mid-stage EscharEx study  2021/06/09 20:37:43 Seeking Alpha
   MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design Study  2021/06/09 20:30:00 Intrado Digital Media
Interim Assessment Expected by end of July 2021 and Completion of Enrollment by Year-End 2021 Interim Assessment Expected by end of July 2021 and Completion of Enrollment by Year-End 2021
   MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design StudyInterim Assessment Expected by end of July 2021 and Completion of Enrollment by Year-End 2021  2021/06/09 00:00:00 BioSpace
MediWound Ltd. (Nasdaq: MDWD), today announced that the enrollment target of patients for an interim assessment of its EscharEx® U.S. phase 2 adaptive design study for the treatment of venous leg ulcers (VLUs) has been achieved, and interim assessment is expected by the end of July 2021.
   MediWound Announces Peer-Reviewed Paper of a Case Series Report of Basal Cell Carcinoma Published in the Open Dermatology Journal  2021/06/07 00:00:00 BioSpace
MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, announced that a peer-reviewed publication of a case series report of basal cell carcinoma destruction by a concentrate of proteolytic enzymes enriched in bromelain has been published in the Open Dermatology Journal.
   MediWound signs UAE burns treatment distribution deal  2020/12/15 12:36:53 Globes English
Under the terms of the agreement, Ghassan Aboud Group will have exclusive rights to market and distribute NexoBrid in the UAE.
   MediWound to Report Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 10, 2020  2020/11/02 21:01:00 GlobeNewswire
YAVNE, Israel, Nov. 02, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative…
   Wound Debridement Market Size Estimation, Outbreak Impact Analysis, Key Insights and Application By 2027 | Coloplast, Misonix, Smith & Nephew, Medtronic, MediWound  2020/10/06 15:31:06 OpenPR
Increase in aging population, rise in prevalence of diabetes escalates incidence of chronic wounds, and growth in obesity levels drive the market. In addition, reimbursement policy and rise in demand for better healthcare fuels the market. However, possible complications after
   MediWound to Report Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on August 6, 2020  2020/07/28 12:00:00 GlobeNewswire
YAVNE, Israel, July 28, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative…
   MediWound : Company Factsheet | MarketScreener  2020/06/07 15:51:03 MarketScreener
MediWound Snapshot Validated breakthrough platform technology with commercial product - NexoBrid®, and promising late-stage product… | June 7, 2020
   MediWound to Report Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 10, 2020  2020/11/02 21:01:00 GlobeNewswire
YAVNE, Israel, Nov. 02, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative…
   Wound Debridement Market Size Estimation, Outbreak Impact Analysis, Key Insights and Application By 2027 | Coloplast, Misonix, Smith & Nephew, Medtronic, MediWound  2020/10/06 15:31:06 OpenPR
Increase in aging population, rise in prevalence of diabetes escalates incidence of chronic wounds, and growth in obesity levels drive the market. In addition, reimbursement policy and rise in demand for better healthcare fuels the market. However, possible complications after
   MediWound to Report Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on August 6, 2020  2020/07/28 12:00:00 GlobeNewswire
YAVNE, Israel, July 28, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative…
   MediWound : Company Factsheet | MarketScreener  2020/06/07 15:51:03 MarketScreener
MediWound Snapshot Validated breakthrough platform technology with commercial product - NexoBrid®, and promising late-stage product… | June 7, 2020
   Zacks.com featured highlights include: MediWound, Issuer Direct, BWX Technologies and Teekay Tankers  2020/05/27 14:29:00 Zacks Investment Research
Zacks.com featured highlights include: MediWound, Issuer Direct, BWX Technologies and Teekay Tankers

 関連キーワード  (医薬品 米国株 メディウ―ンド MDWD MediWound Ltd.)

 twitter  (公式ツイッターやCEOツイッターなど)